Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 7, 2015, Pages 780-786

  Dawson, R ^a   Narunsky, K ^a   Carman, D ^a   Gupte, N ^b   Whitelaw, A ^c   Efron, A ^d   Barnes, G L ^d   Hoffman, J ^d   Chaisson, R E ^d   McIlleron, H ^e   Dorman, S E ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Byramjee Jeejeebhoy Medical College   (India)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Mycobacterium; Rifampicin; Rifamycin; RPT; TB; Therapeutics

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ETHAMBUTOL; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CULTURE MEDIUM; DIARRHEA; DIRECTLY OBSERVED THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME BLOOD LEVEL; FEMALE; HEMATOLOGIC DISEASE; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SPUTUM CULTURE; SPUTUM SMEAR; SURVIVAL; THORAX PAIN; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; MICROBIOLOGY; SOUTH AFRICA; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; SOUTH AFRICA; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84930813893     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0868     Document Type: Article

References (25)

1. Abu-Raddad L J, Sabatelli L, Achterberg J T, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009; 106: 13980-13985.
2. Mitchison D A. Treatment of tuberculosis. The Mitchell Lecture 1979. J R Coll Physicians Lond 1980; 14: 91-99.
3. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin. Chest Med 1980; 1: 231-241.
4. Mitchison D A. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
5. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118- 2124.
6. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541- 1546.
7. Long M, Snider D, Farer L. US Public Health Service cooperative trial of three rifampicin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 879-894.
8. Jindani A, Aber V, Edwards E, Mitchison D. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949.
9. Sirgel F A, Fourie P B, Donald P R, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 171: 108.
10. Diacon A, Patientia R, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51: 2994-2996.
11. Heifets L B, Lindholm-Levy P J, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 626-630.
12. Keung A, Eller M G, McKenzie K A, Weir S J. Single and multiple dose pharmacokinetics of rifapentine in man: Part II. Int J Tuberc Lung Dis 1999; 3: 437-444.
13. Langdon G, Wilkins J J, Smith P J, McIlleron H. Consecutivedose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004; 8: 862-867.
14. Bemer-Melchior P, Bryskier A, Drugeon H B. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 2000; 46: 571-576.
15. Burman W J, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-341.
16. Rosenthal I M, Zhang M, Williams K N, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLOS MED 2007 4: e344.
17. Rosenthal I M, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178: 989-993.
18. Rosenthal I M, Tasneed R, Peloquin C A, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56: 4331-4340.
19. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10: 1-10.
21. Clopper C J, Pearson E S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
22. Lang T. Adaptive trial design: could we use this approach to improve clinical trials in the field of global health? Am J Trop Med Hyg 2011; 85: 967-970.
23. Dorman S E, Savic R M, Goldberg S, et al.; Tuberculosis Trials Consortium. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 2015; 191: 333-343.
24. Savic RM, Weiner M, MacKenzie WW, et al. for theTuberculosis Trials Consortium of the Centers for Disease Control and Prevention 2013. PKPD analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trials Consortium studies 29 and 29X. 6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs. Denver, CO, USA, 9 September 2013. [Abstract 11, p 11] http://regist2.virology-education.com/abstractbook/programbook-6thTB-PK.pdfAccessed March 2015.
25. Dorman S E, Goldberg S, Stout J E, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium. J Infect Dis 2012; 206: 1030-1040.